Global Breast Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

02/feb/2018 06:39:10 sai krishna Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Breast cancer is the disease occurs when uncontrolled growth of malignant cells in the breast tissue that is most commonly occurs in female than men. Treatment of breast cancer depends on various factors such as the type of breast cancer, the size of a tumour, stage of breast cancer and the grade of cancer cells. The breast cancer can be treated by various therapies such as radiation therapy, chemotherapy, hormone therapy, targeted therapy and bone-directed therapy. The common signs and symptoms associated with breast cancer include change in the breast shape, forming of lumps in the breast, dimpling of skin, and red scaly patches on the skin. In severe conditions, bone pain, swelling of lymph nodes, problems in respiration, and yellow skin may appear. The breast cancer commonly occurs due to drinking alcohol, being female, obesity, ionizing radiation, family history and older age among others. The breast cancer is diagnosed by taking a biopsy of lump. After the diagnosis, further tests are carried to determine the cancer stage and suitable treatment for the disease.

The global breast cancer treatment market is expected to increase with significant CAGR due to increasing prevalence and incidence of breast cancer cases. Rising awareness about breast cancer stages and treatment, government initiatives, and improving healthcare infrastructure are driving the breast cancer treatment market. Moreover, the rise in the healthcare expenditure, increase in the diabetic and obese population, increased spending on medicines, increasing consumption of alcohol and tobacco, and rising female population age of 65 years and above are expected to fuel the breast cancer treatment market over the forecast period. Furthermore, increase in the investments in research and developments, development of targeted drug delivery systems, and advancement in cancer biology & pharmacology might boost the breast cancer treatment market. However, drug development challenges in developing countries, long-term side effects of drugs, high costs associated with drug development, stringent regulatory guidelines, and patent expiry of drugs might hamper the growth of breast cancer treatment market in the forecast years.


A sample of this report is available upon request @


The breast cancer treatment market is segmented based on the treatment mechanism, treatment type, and distribution channel

Based on treatment mechanism, the breast cancer treatment market has been segmented into the following:

·        Local

·        Adjuvant

·        Neoadjuvant

·        Systemic


Based on drug class, the breast cancer treatment market has been segmented into the following:

·        Chemotherapy

·        Anthracyclines

·        Antimetabolites

·        Epothilones

·        Taxanes

·        Alkylating agents

·        Hormonal therapy

·        Aromatase inhibitors

·        Selective Oestrogen-receptor modulators


Based on the distribution channel, the breast cancer treatment market has been segmented into the following:

·        Hospital Pharmacies

·        Retail Pharmacies

·        Online Pharmacies


To view TOC of this report is available upon request @


Global breast cancer treatment market is in developing stage, owing to increase in the prevalence rate of breast cancer disease. According to World Health Organization, about 2000 new cases in men and approximately 200,000 new breast cancer cases in women are diagnosed. Most of the pharmaceutical companies in breast cancer treatment market are focus on research and development activities, strategic collaborations, acquisitions & mergers, and product launches for the development of their revenue in the breast cancer treatment market. For instance, in March 2017, Novartis has received FDA approval for its drug kisqali (ribociclib, LEE011) used as first-line treatment for the HR+/HER2 metastatic breast cancer along with aromatase inhibitor. Similarly, In September 2013, The U.S. Food and Drug Administration granted the accelerated approval for Perjeta (pertuzumab) used in the treatment of early stage breast cancer treatment before surgery. The innovation of some innovative therapy with better success rate is expected to offer a good opportunity for breast cancer treatment market.


Need more information about this report @


Some of the players in breast cancer treatment market are AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Sanofi (France), Pfizer, Inc (U.S.). Sun Pharmaceutical Industries Ltd (India), Actavis, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Bayer AG (Germany), Teva Pharmaceutical Industries. Ltd. (Israel), Puma Biotechnology, Inc. (U.S.), and OncoGenex Pharmaceuticals Inc. (U.S.) to name a few.

Get access to full summary @


About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firms. We adopt and implement research methods to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customized market research services based on our client needs.

Precision Business Insights mission is to provide high-quality market research reports and generate key insights to our clients. PBI's approachable strategies are to help clients to make key decisions for business growth.

Precision Business Insights vision companies to provide agile, accurate, and actionable market insights


Contact to Precision Business Insights,


Kemp House,

152 - 160 City Road,

London EC1V 2NX


Toll Free (US): + 1-866-598-1553


Website @

blog comments powered by Disqus è un servizio offerto da Factotum Srl